Sheena K Aurora (S K Aurora)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 7

Top Topics

Cardiovascular Risk Factors

Replacement Therapy

Aortic Dissection

Top Venues

European journal of neurology

Current pain and headache reports

This page only lists publications with an associated author ORCID identifier.

Publications

Rima M Dafer, Gretchen E Tietjen, John F Rothrock, Robert E Vann, Stephen B Shrewsbury, Sheena K Aurora
Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraine. Headache 64 (8) (2024)
Rima M Dafer, Gretchen E Tietjen, John F Rothrock, Robert E Vann, Stephen B Shrewsbury, Sheena K Aurora
Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraine. Headache (2024)
Rima M Dafer, Gretchen E Tietjen, John F Rothrock, Robert E Vann, Stephen B Shrewsbury, Sheena K Aurora
Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraine. Headache 64 (8) (2024)
Victor S Wang, Justin Kosman, Hsiangkuo Yuan, Clinton G Lauritsen, Stephen Shrewsbury, Sheena K Aurora, Mary Hopkins, Stephen Silberstein
Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study. Headache (2023)
Linda Nguyen, Nada Hindiyeh, Sutapa Ray, Robert E Vann, Sheena K Aurora
The Gut-brain Connection and Episodic Migraine: an Update. Current pain and headache reports (2023)
P J Goadsby, G M Terwindt, D D Ruff, J H Ford, A Tockhorn-Heidenreich, V L Stauffer, Sriram Govindan, Sheena K Aurora
Response to 'Do different treatment strategies of galcanezumab have similar effect on migraine?' European journal of neurology 27 (5) (2020)
J Ailani, E Pearlman, Q Zhang, A J Nagy, K Schuh, Sheena K Aurora
Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies. European journal of neurology 27 (3) (2019)